{"schema_version":"secwatch.filing_event.v1","accession":"0001798749-23-000023","form_type":"8-K","ticker":"JBIO","cik":"0001798749","company_name":"Jade Biosciences, Inc.","filed_at":"2023-04-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.643302+00:00","generated_at":"2026-06-17T05:58:05.375660+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aerovate Therapeutics enters into $75M ATM equity offering with BofA Securities","bullets":["Entered into ATM Sales Agreement with BofA Securities to sell up to $75M of common stock.","Shares sold at market prices; BofA receives 3% commission on gross proceeds.","Company not obligated to sell any shares; may suspend or terminate offering at any time.","Offering made under existing effective shelf registration statement on Form S-3."],"urls":{"canonical":"https://secwatch.observer/filing/0001798749-23-000023","json":"https://secwatch.observer/filing/0001798749-23-000023.json","markdown":"https://secwatch.observer/filing/0001798749-23-000023.md","text":"https://secwatch.observer/filing/0001798749-23-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1798749/000179874923000023/0001798749-23-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1798749/000179874923000023/tmb-20230405x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T05:58:05.375660+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"34b86745af750de0cdcd54afb68b7e43326f67bc","claim":"Jade Biosciences, Inc. entered into ATM Equity Offering SM Sales Agreement with BofA Securities, Inc. valued at up to $75,000,000 (effective 2023-04-05).","evidence_excerpt":"On April 5, 2023, Aerovate Therapeutics, Inc. (the “Company”) entered into an ATM Equity Offering SM Sales Agreement (the “Sales Agreement”), with BofA Securities, Inc. (“BofA”) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $75,000,000 (the “Shares”) through BofA as its sales agent or to BofA as principal for its own account.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1798749/000179874923000023/0001798749-23-000023-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"BofA Securities, Inc."},{"label":"Value","value":"up to $75,000,000"},{"label":"Effective","value":"2023-04-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}